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Abstract
Background: Non-sinonasal neuroendocrine carcinomas (NSNECs) of the head and neck are considered an
unfrequent clinico-pathological entity. Combined modality treatment represents an established therapeutic option
for undifferentiated forms where distant metastasis is a common pattern of failure.
Methods: We report on a case of NSNEC treated with sequential chemo-radiation consisting of 6 cycles of
cisplatin and etoposide followed by loco-regional radiation to the head and neck and simultaneous prophylactic
cranial irradiation to prevent from intracranial spread, delivered with helical tomotherapy with the ‘hippocampal
avoidance’ technique in order to reduce neuro-cognitive late effects.
Results: One year after the end of the whole combined modality approach, the patient achieved complete
remission, with no treatment-related sub-acute and late effects.
Conclusions: The present report highlights the importance of multidisciplinary management for NSNECs of the
head and neck, as the possibility to achieve substantial cure rates with mild side effects with modern radiotherapy
techniques.
Keywords: Radiotherapy, Tomotherapy, Non-sinonasal neuroendocrine carcinoma, Head and neck, Hippocampus
avoidance, Prophylactic cranial irradiation
Introduction
Tumours of neuroendocrine differentiation arising within
the head and neck region are considered an extremely rare
clinico-pathological entity [1]. They have been described
in several anatomical sites such as upper airways (trachea,
larynx, nose, paranasal sinuses), ear, tongue and salivary
glands [2,3]. Some Authors have proposed a frame distinc-
tion between sinonasal neuroendocrine carcinomas
(SNNECs) and non-sinonasal neuroendocrine carcinomas
(NSNECs) in terms of pathological classification and ther-
apeutic options [1,4]. SNNEC are divided into 4 main his-
tological categories, namely esthesioneuroblastoma,
undifferentiated carcinoma, neuroendocrine carcinoma
and small cell undifferentiated carcinoma and might
deserve a multimodality treatment approach regardless of
their differentiation [1,4]. Conversely, NSNECs are
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any medium, provided the original work is properly cited.represented by undifferentiated (small cell or large cell
subtypes), moderately (atypical carcinoid) and well-differ-
entiated (typical carcinoid) carcinomas [1,5]. They mainly
arise within the larynx (where they represent 0.6-1% of all
epithelial cancers), particularly in the epiglottis and supra-
glottic region (aryepiglottic folds and arytenoids) [6]. They
predominantly affect males, smokers and present with
locally advanced node positive disease [1,7]. Conservative
surgery (where possible) might be considered adequate for
well-differentiated subtypes, while combined modality
treatment (chemotherapy and radiotherapy) is considered
a mainstay option for undifferentiated forms where distant
metastasis represent the major pattern of failure [1]. We
herein report on a case of NSNEC of unknown primary
site treated with a sequential chemo-radiation approach
consisting of 6 cycles of cisplatin (DDP) and etoposide
(VP-16) followed by loco-regional radiation to the head
and neck region and simultaneous prophylactic cranial
irradiation (PCI) to prevent from intracranial spread, deliv-
ered with helical tomotherapy (HT) with the ‘hippocampal
avoidance’ (HA) technique in order to reduce radiation-
induced neuro-cognitive late effects [8].
Case report
A 53 years old caucasian man was referred to our Institu-
tion Hospital due to the sudden appearance of a right
latero-cervical enlarged lymphnode with no symptoms
complained. He had a previous medical history of child-
hood tonsillectomy, appendectomy, acute bacterial epidi-
dymitis and asymptomatic hepatitis A infection. He was a
non-smoker and had a low-moderate alcohol intake at
meals. Physical examination of the neck region showed a
3-cm hard and fixed adenopathy close to the posterior
belly of the right digastric muscle. He underwent, at first,
a pharyngo-laryngoscopy procedure that revealed a macro-
scopic tongue tonsil hypertrophy. A total body CT-scan
demonstrated two enlarged lymphnodes (35 and 12 mm
in diameter) in the right upper neck between the sub-
mandibular group (level Ib) and the upper anterior jugular
group (level IIA) according to Robbins classification with
an adjunctive level IIA left node (15 mm in diameter) [9];
thickening of the base of the tongue could also be
observed (Figure 1). He underwent an excisional biopsy of
the right neck and a punch biopsy of the base of the ton-
gue; histological findings of the lymphnode specimen
documented undifferentiated small cell carcinoma (typical
oat cells pattern; positive staining for AE1 and AE3 Cyto-
keratin, Chromogranin A and CD 56) with a Ki67 labelling
index of 80%; base of the tongue was negative for tumour
cells (Figure 2). For staging purposes a
18 F-deoxyglucose-
CT-positron emission tomography (CT-PET scan) was
performed showing focal uptake within the oropharynx
and left neck (Figure 1). Using flexible fiber-optic endo-
scopy he underwent directed bilateral biopses of the most
likely primary tumour sites (nasopharynx, tongue base,
tonsils, piriform sinus) with negative findings. Adjunctively
a lingual tonsillectomy was performed with the evidence of
hyperplastic lingual tonsillitis. At the end of diagnostic
work-up: small cell undifferentiated NSNEC of unknown
primary site (AJCC-UICC stage cTxN2bM0) was pointed
out. Multimodality therapeutic approach was chosen con-
sisting of induction CT followed by consolidation radia-
tion; 6 cycles of the PE regimen were planned (Cisplatin
75 mg/m
2 day1 and Etoposide 100 mg/m
2 days 1,2,3 every
21 days). Intermediate CT and PET restaging was per-
formed after 3 PE cycles, with the evidence of the persis-
tent thickening and uptake within the tongue base. The
patient underwent a new biopsy of the nasopharynx and
base of the tongue with no tumour observed. The che-
motherapy program was completed with mild acute toxi-
city (grade 2 alopecia ad grade 1 asthenia according to
CTCAE v 4.0). A re-evaluation with functional and ana-
tomic imaging (CT-PET scan) was carried out at the end
of the CT program: complete remission (CR) was
achieved. Thirty days after, the patients was planned to
receive consolidation head and neck region radiation and
PCI delivered with the TomoTherapy Hi-Art II system
(TomoTherapy Inc,. Madison, WI) with the HA technique,
as reported by Gondi et al. [10]. In order to evaluate basal
neuro-cognitive functions, Mini Mental State Examination
(MMSE) test was performed before radiation leading to a
30 out of 30 score. After proper immobilization (flat head-
board and head-shoulders thermoplastic mask) and 2.5
mm slice thickness planning CT, target volumes and
organs at risk contours were created within the Philips
Pinnacle P3 v9.1 treatment planning system (Philips Medi-
cal System, Eindhoven, The Netherlands). The head and
neck region volumes comprised the whole pharingo-laryn-
geal axis (from the roof of the naso-pharynx to the infra-
glottic larynx) and the bilateral neck (level Ib to V and
retro-pharyngeal nodes according to Robbins classifica-
t i o n )w i t ha5m me x p a n s i o nf r o mC T Vt oP T Vt o
account for set up errors [9] (Figure 3a and 3c). The PCI
volume comprehended the whole brain from the vertex to
the occipital foramen (with the same 5 mm CTV to PTV
expansion) (Figure 3a and 3c). For a correct delineation of
the hippocampal regions, the patient underwent three-
dimensional spoiled gradient axial magnetic resonance
imaging (MRI) scans (3D-SPGR), standard axial and fluid
attenuation recovery (FLAIR) scans and T2-weighted
acquisitions, as suggested by Gondi et al. [10]. Semi-auto-
matic rigid registration was performed between planning
CT scans and MRI scans. The hippocampus was con-
toured on T1-weighted MRI axial sequences (T1-hypoin-
tense signal medial to the temporal horn) from the most
caudal extent of the temporal horn to the lateral edges of
the quadrageminals cisterns along the anterior-posterior
axis (see Gondi et al. for details, [10]) (Figure 3b and 3d).
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Page 2 of 9A volumetrically isotropic 5 mm expansion was generated
around the hippocampus to create the ‘hippocampal
avoidance volumes’ ( H A V s )f o ra p p r o p r i a t ed o s ef a l lo f f
between hippocampus and whole brain PTV (whole brain
volume minus bilateral HAVs). Taking into account his-
tology and complete remission status after induction che-
motherapy, dose prescription was 60 Gy delivered in 30
fractions (2 Gy daily) for the head and neck region and
25.2 Gy in 14 fractions (1.8 Gy daily) for the whole brain
PTV minus HAVs. The prescription dose was defined to
the mean PTV and the 95% percentage PTV volume
should be covered at least by 95% of the prescribed dose.
In order to minimize late effects, conventional fractiona-
tion was employed for the 2 locations. Hence, the substan-
tial difference in the number of fractions (30 vs 14) did
not allow for the use simultaneous integrated boost (SIB)
that would have lead to hypofractionation for the head
and neck region. Therefore 2 different plans were gener-
ated. Isodose visualization was made importing both plans
on the Oncentra Masterplan v 3.0 software (Nucletron,
Veendhal, The Netherlands), since Tomotherapy does not
allow for visualization of summed plans. Inverse planning
algorithm constraints for head and neck regions organs at
risks were as suggested by the Quantitative analysis of nor-
mal tissue effects in the clinic (QUANTEC) [11-14]. Dose
constraints for the hippocampus (maximum dose 6 Gy
and V3 ≤ 20%) and HAVs (maximum dose 25.2 Gy and
V20 ≤ 20%) were adapted from Gondi et al. [10]. Metrics
employed for tomotherapy planning were field width (FW)
2.5 cm, pitch 0.287, modulation factor (MF) planned 3.0
(actual 2.105) for the head and neck region and FW 1 cm,
pitch 0.215, MF planned 3.2 (actual 2.7799) for whole
brain radiation. Directional blocking was used only for
lenses. The so obtained dose distribution is shown in Fig-
ures 4, 5. Dosimetric parameters are shown in Table 1.
Radiation treatment was well tolerated with mild acute
toxicity (grade 1 oral mucositis, skin reaction and xerosto-
mia according to RTOG toxicity scale). No treatment
Figure 1 Enlarged level Ib (star) and IIA (arrow) right nodes (Figure 1a-b) and level IIA left node (circle; Figure 1a) with thickening
of the base of the tongue (blast; Figure 1a) at diagnostic CT scan; base of the tongue hyperaccumulation at 18-FDG- PET scan
(Figure 1c-d).
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Page 3 of 9interruptions occurred. Post-treatment re-evaluation
showed complete remission at morphological and func-
tional imaging with one year follow up. Grade 1 LENT-
SOMA xerostomia could be detected as the only radia-
tion-induced sequelae. Finally, MMSE results were
unchanged compared to baseline.
Discussion
NSNECs of the head and neck region are widely uncom-
mon and therefore clinical and therapeutic informations
are scanty. In addition, the issue is beclouded by the slen-
derness of the published literature (mainly available
throughout anecdotal reports) and by the heterogeneity
of the histological sub-types and anatomical sites of pre-
sentation of the medical cases described. However some
informative studies are available. To our knowledge, the
largest case series of NSNECs published is the one by the
MD Anderson Cancer Center: 23 patients were treated
between 1984 and 2001 (median age 64 years; mainly
smokers; predominant laryngeal primary tumours; locally
advanced disease at diagnosis) [1]. The cohort underwent
different treatment strategies including surgery, radiation
and chemotherapy (in different combinations). With a
median follow up of 40 months, 2-year and 5-year overall
survival (OS) rates were 53% and 33%, respectively, while
corresponding disease free survival (DFS) were 41% and
25%. Interestingly, since NSNEC is highly responsive to
CT, the Authors reported that the inclusion of a DDP
and VP-16 chemotherapeutic regimen in the multimodal-
ity treatment approach approximately doubled the 2 year
OS and DFS. The most common pattern of failure is dis-
tant metastasis (DM) with a 2-year and 5-year rate of
54% and 71% respectively. The addition of CT in the
therapeutic strategy reduced by one-half (79% vs 39%; p
= 0.006) the 2-year rate of DM if compared to local ther-
apy alone (either in univariate and multivariate analysis)
[1]. Among DMs, intracranial spread often occurs with a
2-year and 5-year rate of 25% and 44% respectively.
Moreover, isolated brain metastasis are quite frequent
(21% and 41% of 2-year and 5-year rates). Local failure
Figure 2 Oat cells pattern at hematoxylin-eosin staining (Figure 2a); immunohistochemistry positive staining for AE1 and AE3
Cytokeratin (Figure 2b), Chromogranin A (Figure 2c) and CD 56 (Figure 2d).
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Page 4 of 9(LF) is infrequent (2-year and 5 year rate of 23%), specifi-
cally almost half of the frequency of comparably staged
squamous cell carcinoma of the head and neck region
[ 1 5 ] .R a d i a t i o nt h e r a p yd o s e( r a n g e4 4 - 7 2G y )d i dn o t
correlate with LF (p = 0.23). CT did not prevent from LF
(p = 0.91); however half of the patients with LF did not
achieve complete remission (CR) after induction CT.
Thereby, some general conclusions might be drawn. Sur-
gical approaches should be limited to well-differentiated
neuroendocrine carcinoma histological subtypes (typical
carcinoids or carcinoid-like tumours), as it is for other
body districts. Combined modality treatment consisting
of chemotherapy and local radiotherapy should be
strongly considered for moderately and poorly differen-
tiated NSNECs. The preferable timing of the CT-RT
combination is the sequential approach. Even if concur-
rent chemo-radiation has reached satisfactory evidence
over sequential chemo-radiation in SCLC, induction CT
and subsequent consolidation RT for complete or very
good partial responders might be considered an efficient
and less toxic approach for NSNECs, since concomitant
CT-RT has not proven to improve early complete
response rate, local control or survival [1]. However if
macroscopic residual disease is present after induction
CT, thereafter concurrent CT-RT or salvage surgery
should be considered, since local control become the pre-
dominant clinical issue. The high rate of isolated brain
metastasis is consistent with the fact that central nervous
systems might harbour microscopic disease at diagnosis,
thus calling for the need of eventual PCI. Generally, PCI
has an established role in preventing the disabling symp-
toms due to intracranial metastasis and gives a survival
benefit for patients affected with SCLC gaining intra-
thoracic CR after combination therapy [16,17]. The
aforementioned evidence might be translated in the clini-
cal setting of NSNECs, considering the high risk of brain
spread, suggesting the option of PCI for patients achiev-
ing CR after induction CT. Hence, the radiation strategy
for this subset of patients might consist in large treat-
ment volumes irradiated at first with a combination of
Figure 3 Target volumes including the head and neck region and the whole brain with concomitant sparing of the bilateral
hippocampal regions (Figure 3a-c); fusion MRI employed for appropriate delineation of the hippocampus (Figure 3b-d).
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Page 5 of 9PCI (dose range of 25-30 Gy delivered with conventional
fractionation to reduce late effects) and consolidation RT
to the head and neck region (primary site of tumour and
corresponding draining lymphnodes) and a subsequent
prosecution to head and neck only up to 60-70 Gy
according to the appropriate clinical context. This
approach supposedly avoids concerns regarding field
junctions and isodose overlapping. Helical tomotherapy
is particularly well-suited for this type of treatment since
it is constituted by a continuously rotating, helical fan
beam carved by a binary multileaf collimator mounted
on a ring gantry that rotates around the treatment couch
as it slowly progress within the gantry bore, through the
beam delivery plane: therefore the length of the target
volume does not represents a limiting factor since the
equipment is able to proceed spirally around the patient
for distances up to 160 cm [18,19]. PCI, as other typolo-
gies of cranial irradiation, might cause some grade of
neurocognitive toxicity: late toxicity is described in long-
term brain metastasis survivors submitted to whole brain
radiotherapy in terms of cognitive deterioration and cere-
bellar dysfunction [20]. Moreover and early component
of neurocognitive decline, involving verbal and short-
term memory recall, has also been described with 1-4
months from WBRT for brain metastasis, regardless of
response to treatment (diversely than executive and fine
motor functions) [8]. Since the hippocampus has a cru-
cial role in supporting memory function, its sparing pos-
sibly allows for a minimization of radiation-induced
cognitive late effects, with possibly no detrimental effects
on local control given the fact that the vast majority of
brain metastasis arise beyond > 5 mm from the hippo-
campal region [21]. The hypothesis of a possible neuro-
cognitive benefit of hippocampal avoidance in presently
being tested by the RTOG within a Phase II prospective
trial (namely RTOG 0933) which evaluates the effects on
onset, frequency and severity of neurocognitive disorders
in patients undergoing whole brain radiotherapy with
concomitant hippocampus sparing for intracranial metas-
tasis [8]. Given all the aforementioned background we
Figure 4 Planning results in terms of isodoses distribution with organs at risk sparing, namely hippocampus (Figure 4a-d), spinal cord
(Figure 4a), parotid glands (Figure 4b), ocular bulbs and lens (Figure 4c).
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Page 6 of 9Figure 5 Dose-volume histogram for target volumes and main intracranial organs at risk.
Table 1 Dosimetric parameters overview
OARs Dosimetric constraints Dosimetric results
R hippocampus Dmax < 6 Gy V3G y< 20% Dmax 9,9 Gy Dmean 6,5 Gy
Median dose 6,3 Gy
L hippocampus Dmax < 6 Gy V3G y< 20% Dmax 10,0 Gy Dmean 6,5 Gy
Median dose 6,2 Gy
R HAV Dmax <2 5G yV 20 Gy < 20% Dmax 22,4 Gy V20 Gy 2,00%
L HAV Dmax <2 5G yV 20 Gy < 20% Dmax 23,5 Gy V20 Gy 3,00%
R lens Dmax < 6 Gy Dmax 4,8 Gy
L lens Dmax < 6 Gy Dmax 4,7 Gy
R ocular bulb Dmax <5 4G yD mean <3 5G y D max 17,8 Gy Dmean 6,8 Gy
L ocular bulb Dmax <5 4G yD mean <3 5G y D max 15,6 Gy Dmean 6,3 Gy
R optic nerve Dmax <5 4G y D max 25,9 Gy
L optic nerve Dmax <5 4G y D max 25,6 Gy
Optic chiasm Dmax <5 4G y D max 28,3 Gy
Spinal cord Dmax <4 5G y D max 28,6 Gy
Brainstem Dmax <5 4G y D max 39,4 Gy
Oral cavity Dmean <4 5G y D mean 40,7 Gy
R cochlea Dmean <3 5G y D mean 38,1 Gy
L cochlea Dmean <3 5G y D mean 35,1 Gy
Pituitary gland Dmax <4 0G yD mean <3 5G y D max 29,9 Gy Dmean 28,1 Gy
Glottic larynx Dmean <5 0G yV 60 Gy < 45% Dmean 58,7 Gy V60 Gy 47,00%
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Page 7 of 9chose to treat our patient (who achieved CR after induc-
tion CT) with consolidation radiation to the head and
neck region and simultaneous PCI with the HA techni-
que. The first 14 fraction were delivered both to the
whole brain and head and neck region (a total of 25.2 Gy
and 28 Gy respectively), while the remaining 16 fractions
(2 Gy daily) were only delivered to the head and neck
that received up to 60 Gy (2 different plans were gener-
ated). Planning and optimization were absolutely challen-
ging, since dosimetric constraints to the hippocampus
revealed hard to be respected due to the dosimetric con-
tribute given by the head and neck region receiving 60
Gy and located only few centimetres below: thus bilateral
hippocampus received a maximum dose of 7 Gy (instead
of the planned 6 Gy), but the fact might be mitigated by
the conventional fractionation employed. Even though it
has been suggested that MMSE might have low sensitiv-
ity and specificity for testing neurocognitive function in
patients affected with brain metastasis (conversely being
well-suited for dementia evaluation) if compared to other
examinations such as Hopkins Verbal Learning Test
(HVLT), we chose this text in order to have a simple,
agile and generally reliable metric to assess neurocogni-
tion [22,23]. At last the whole combined modality
approach gave excellent short-term results in terms of
tumor control and treatment-related toxicity.
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